Differential effect on cell-mediated immunity in human volunteers after intake of different lactobacilli

Clinical and Experimental Immunology

Volumn 172, Issue 2, 2013, Pages 321-332

  Rask, C ^a   Adlerberth, I ^a   Berggren, A ^b   Ahren I L ^b   Wold, A E ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Probi AB   (Sweden)

Author keywords

Lactobacilli; NKT cells; Placebo controlled; Probiotics; T cell activation

Indexed keywords

CD45RO ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2 RECEPTOR ALPHA; PLACEBO; PROBIOTIC AGENT;

ADULT; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GRANULOCYTE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; LACTOBACILLUS FERMENTUM; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; MEDIATOR RELEASE; MEMORY T LYMPHOCYTE; NATURAL KILLER T CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PEYER PATCH; PHAGOCYTOSIS; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS LUNDENSIS; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADOLESCENT; ADULT; ANTIGENS, CD45; BACTERIAL ADHESION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTESTINAL MUCOSA; LACTOBACILLUS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PLACEBOS; PROBIOTICS; PSEUDOMONAS; YOUNG ADULT;

EID: 84876074608     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12055     Document Type: Article

References (57)

1. Schrezenmeir J, de Vrese M. 2001 Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr 2001; 73 (Suppl 2):361S-364.
2. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989; 66:365-378.
3. Borriello SP, Hammes WP, Holzapfel W etal. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36:775-780.
4. Muñoz JA, Chenoll E, Casinos B etal. Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl Environ Microbiol 2011; 77:8775-8783.
5. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344:1046-1049.
6. Johnston BC, Goldenberg JZ, Vandvik PO, Sun X, Guyatt GH. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011; (11):CD004827. doi: 10.1002/14651858.CD004827.pub3.
7. Cremonini F, Di Caro S, Nista EC etal. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16:1461-1467.
8. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324:1361.
9. Abdelouhab K, Rafa H, Toumi R, Bouaziz S, Medjeber O, Touil-Boukoffa C. Mucosal intestinal alteration in experimental colitis correlates with nitric oxide production by peritoneal macrophages: effect of probiotics and prebiotics. Immunopharmacol Immunotoxicol 2012; 34:590-597.
10. Shanahan F. Probiotics in inflammatory bowel disease-therapeutic rationale and role. Adv Drug Deliv Rev 2004; 56:809-818.
11. Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M. Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002; 16 (Suppl 4):13-19.
12. Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000; 15:489-493.
13. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Therapy 2012; 35:403-413.
14. Ringel Y, Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol 2011; 45 (Suppl):S145-148.
15. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95:1231-1238.
16. Drago L, Iemoli E, Rodighiero V, Nicola L, De Vecchi E, Piconi S. Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J Immunopathol Pharmacol 2011; 24:1037-1048.
17. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357:1076-1079.
18. Rosenfeldt V, Benfeldt E, Nielsen SD etal. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111:389-395.
19. Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr 2012; 107:1505-1513.
20. Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr 1999; 18:43-50.
21. Bertolami MC, Faludi AA, Batlouni M. Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. Eur J Clin Nutr 1999; 53:97-101.
22. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr 2001; 20 (2 Suppl.):149-156.
23. Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr 2000; 54:263-267.
24. Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001; 74:833-839.
25. Chiang BL, Sheih YH, Wang LH, Liao CK, Gill HS. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr 2000; 54:849-855.
26. Paineau D, Carcano D, Leyer G etal. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol 2008; 53:107-113.
27. Fukushima Y, Kawata Y, Hara H, Terada A, Mitsuoka T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998; 42:39-44.
28. de Vrese M, Rautenberg P, Laue C, Koopmans M, Herremans T, Schrezenmeir J. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. Eur J Nutr 2005; 44:406-413.
29. Link-Amster H, Rochat F, Saudan KY, Mignot O, Aeschlimann JM. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994; 10:55-63.
30. Kaila M, Isolauri E, Virtanen E, Arvilommi H. Preponderance of IgM from blood lymphocytes in response to infantile rotavirus gastroenteritis. Gut 1992; 33:639-642.
31. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992; 32:141-144.
32. Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995; 20:333-338.
33. Hessle C, Hanson LA, Wold AE. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin Exp Immunol 1999; 116:276-282.
34. Donkor ON, Ravikumar M, Proudfoot O etal. Cytokine profile and induction of T helper type 17 and regulatory T cells by human peripheral mononuclear cells after microbial exposure. Clin Exp Immunol 2012; 167:282-295.
35. Adlerberth I, Ahrne S, Johansson ML, Molin G, Hanson LA, Wold AE. A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29. Appl Environ Microbiol 1996; 62:2244-2251.
36. Duguid JB, Robertson WB. Mechanical factors in atherosclerosis. Lancet 1957; 272:1205-1209.
37. Hessle C, Andersson B, Wold AE. Gram-positive bacteria are potent inducers of monocytic interleukin-12 (IL-12) while Gram-negative bacteria preferentially stimulate IL-10 production. Infect Immun 2000; 68:3581-3586.
38. Dong H, Rowland I, Tuohy KM, Thomas LV, Yaqoob P. Selective effects of Lactobacillus casei Shirota on T cell activation, natural killer cell activity and cytokine production. Clin Exp Immunol 2010; 161:378-388.
39. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178:1041-1048.
40. Fiorentino DF, Zlotnik A, Vieira P etal. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-3451.
41. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-1220.
42. Barkman C, Martner A, Hessle C, Wold AE. Soluble bacterial constituents down-regulate secretion of IL-12 in response to intact Gram-positive bacteria. Microbes Infect 2008; 10:1484-1493.
43. Rescigno M, Rotta G, Valzasina B, Ricciardi-Castagnoli P. Dendritic cells shuttle microbes across gut epithelial monolayers. Immunobiology 2001; 204:572-581.
44. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15:535-562.
45. Kawano T, Nakayama T, Kamada N etal. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999; 59:5102-5105.
46. Smyth MJ, Thia KY, Street SE etal. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191:661-668.
47. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192:921-930.
48. Exley MA, Bigley NJ, Cheng O etal. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leukoc Biol 2001; 69:713-718. Erratum in: J Leukoc Biol 2001; 70(2):340.
49. Illés Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164:4375-4381.
50. Hong S, Scherer DC, Singh N etal. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol Rev 1999; 169:31-44.
51. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. Alpha/beta-T cell receptor (TCR)+ CD4- CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in non-obese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998; 187:1047-1056.
52. Lehuen A, Lantz O, Beaudoin L etal. Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic non-obese diabetic mice against diabetes. J Exp Med 1998; 188:1831-1839.
53. Gombert JM, Tancrède-Bohin E, Hameg A etal. IL-7 reverses NK1+ T cell-defective IL-4 production in the non-obese diabetic mouse. Int Immunol 1996; 8:1751-1758.
54. Godfrey DI, Kinder SJ, Silvera P, Baxter AG. Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymocytes. J Autoimmun 1997; 10:279-285.
55. Mieza MA, Itoh T, Cui JQ etal. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996; 156:4035-4040.
56. Berggren A, Lazou Ahrén I, Larsson N, Önning G. Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. Eur J Nutr 2011; 50:203-210.
57. Ahrné S, Nobaek S, Jeppsson B, Adlerberth I, Wold AE, Molin G. The normal Lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol 1998; 85:88-94.